<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39346546</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>15</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>Developing an enhanced chimeric permuted intron-exon system for circular RNA therapeutics.</ArticleTitle><Pagination><StartPage>5869</StartPage><EndPage>5882</EndPage><MedlinePgn>5869-5882</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.98214</ELocationID><Abstract><AbstractText><b>Rationale</b>: Circular RNA (circRNA) therapeutics hold great promise as an iteration strategy in messenger RNA (mRNA) therapeutics due to their inherent stability and durable protein translation capability. Nevertheless, the efficiency of RNA circularization remains a significant constraint, particularly in establishing large-scale manufacturing processes for producing highly purified circRNAs. Hence, it is imperative to develop a universal and more efficient RNA circularization system when considering synthetic circRNAs as therapeutic agents with prospective clinical applications. <b>Methods:</b> We initially developed a chimeric RNA circularization system based on the original permuted intron-exon (PIE) and subsequently established a high-performance liquid chromatography (HPLC) method to obtain highly purified circRNAs. We then evaluated their translational ability and immunogenicity. The circRNAs expressing human papillomavirus (HPV) E7 peptide (43-62aa) and dimerized receptor binding domain (dRBD) from SARS-CoV-2 were encapsulated within lipid nanoparticles (LNPs) as vaccines, followed by an assessment of the <i>in vivo</i> efficacy through determination of antigen-specific T and B cell responses, respectively. <b>Results:</b> We have successfully developed a universal chimeric permuted intron-exon system (CPIE) through engineering of group I self-splicing introns derived from Anabaena pre-tRNA<sup>Leu</sup> or T4 phage thymidylate (Td) synthase gene. Within CPIE, we have effectively enhanced RNA circularization efficiency. By utilizing size exclusion chromatography, circRNAs were effectively separated, which exhibit low immunogenicity and sustained potent protein expression property. <i>In vivo</i> data demonstrate that the constructed circRNA vaccines can elicit robust immune activation (B cell and/or T cell responses) against tumor or SARS-CoV-2 and its variants in mouse models. <b>Conclusions:</b> Overall, we provide an efficient and universal system to synthesize circRNA <i>in vitro</i>, which has extensive application prospect for circRNA therapeutics.</AbstractText><CopyrightInformation>Â© The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Chunbo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weibing</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rou</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Key Laboratory of Bioorganic Phosphorus Chemistry &amp; Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qi</LastName><ForeName>Shaolong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Key Laboratory of Bioorganic Phosphorus Chemistry &amp; Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lijun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Guocan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Key Laboratory of Bioorganic Phosphorus Chemistry &amp; Chemical Biology, Department of Chemistry, Tsinghua University, Beijing 100084, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lianqing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center of Translational Medicine, Zibo Central Hospital, Zibo 255036, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiaoyuan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Departments of Diagnostic Radiology, Surgery, Chemical and Biomolecular Engineering, and Biomedical Engineering, Yong Loo Lin School of Medicine and College of Design and Engineering, National University of Singapore, Singapore 119074, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Theranostics Center of Excellence (TCE), Yong Loo Lin School of Medicine, National University of Singapore, Singapore 138667, Singapore.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Molecular and Cell Biology, Agency for Science, Technology, and Research (A*STAR), Singapore 138673, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhida</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan 030001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shanxi Academy of Advanced Research and Innovation, Taiyuan 030032, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Veterinary Medicine, Shanxi Agricultural University, Jinzhong 030801, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079962">RNA, Circular</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000711949">Lipid Nanoparticles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000079962" MajorTopicYN="Y">RNA, Circular</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007438" MajorTopicYN="Y">Introns</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005091" MajorTopicYN="Y">Exons</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">chimeric permuted intron-exon system (CPIE)</Keyword><Keyword MajorTopicYN="N">circular RNA (circRNA)</Keyword><Keyword MajorTopicYN="N">mRNA therapeutics</Keyword><Keyword MajorTopicYN="N">ribozyme</Keyword><Keyword MajorTopicYN="N">size exclusion chromatography</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39346546</ArticleId><ArticleId IdType="pmc">PMC11426236</ArticleId><ArticleId IdType="doi">10.7150/thno.98214</ArticleId><ArticleId IdType="pii">thnov14p5869</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rohner E, Yang R, Foo KS, Goedel A, Chien KR. Unlocking the promise of mRNA therapeutics. Nat Biotechnol. 2022;40:1586â600.</Citation><ArticleIdList><ArticleId IdType="pubmed">36329321</ArticleId></ArticleIdList></Reference><Reference><Citation>Aygun I, Barciszewski J. The forerunners and successful partnerships behind the BioNTech mRNA vaccine. J Appl Genet. 2024;65:47â55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10789661</ArticleId><ArticleId IdType="pubmed">37861886</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G, Noh D, Lee H, Lee S, Kim S, Yoon HY. et al. Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery. Adv Drug Deliv Rev. 2023;199:114973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10290897</ArticleId><ArticleId IdType="pubmed">37369262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA. et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27:2136â43.</Citation><ArticleIdList><ArticleId IdType="pubmed">34728831</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer BA, Beitelshees M, Hill A, Bassett J, Jones CH. Harnessing synthetic biology for advancing RNA therapeutics and vaccine design. NPJ Syst Biol Appl. 2023;9:60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10689799</ArticleId><ArticleId IdType="pubmed">38036580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kameda S, Ohno H, Saito H. Synthetic circular RNA switches and circuits that control protein expression in mammalian cells. Nucleic Acids Res. 2023;51:e24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9976894</ArticleId><ArticleId IdType="pubmed">36642090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft RA, Kowalski PS, Parker-Hale FC, Huang Y, Bisaria N, Anderson DG. RNA Circularization Diminishes Immunogenicity and Can Extend Translation Duration In Vivo. Mol Cell. 2019;74:508â20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724735</ArticleId><ArticleId IdType="pubmed">30902547</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. Signal Transduct Target Ther. 2023;8:341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10493228</ArticleId><ArticleId IdType="pubmed">37691066</ArticleId></ArticleIdList></Reference><Reference><Citation>Petkovic S, Muller S. RNA circularization strategies in vivo and in vitro. Nucleic Acids Res. 2015;43:2454â65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4344496</ArticleId><ArticleId IdType="pubmed">25662225</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Lu Y. Circular RNA: Biosynthesis in vitro. Front Bioeng Biotechnol. 2021;9:787881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670002</ArticleId><ArticleId IdType="pubmed">34917603</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Cheng K, Liu X, An R, Komiyama M, Liang X. Preferential production of RNA rings by T4 RNA ligase 2 without any splint through rational design of precursor strand. Nucleic Acids Res. 2020;48:e54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7229815</ArticleId><ArticleId IdType="pubmed">32232357</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J, Zhang L, Zhang Z, Luo X, Liu Y, Li C. et al. A precise and efficient circular RNA synthesis system based on a ribozyme derived from Tetrahymena thermophila. Nucleic Acids Res. 2023;51:e78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415121</ArticleId><ArticleId IdType="pubmed">37378451</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KH, Kim S, Song J, Han SR, Kim JH, Lee SW. Efficient circular RNA engineering by end-to-end self-targeting and splicing reaction using Tetrahymena group I intron ribozyme. Mol Ther Nucleic Acids. 2023;33:587â98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10457212</ArticleId><ArticleId IdType="pubmed">37637208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Wei H, Zhang K, Li Z, Wei T, Tang C, A flexible, efficient, and scalable platform to produce circular RNAs as new therapeutics. bioRxiv. 2022. 2022. 05. 31.494115.</Citation></Reference><Reference><Citation>Rausch JW, Heinz WF, Payea MJ, Sherpa C, Gorospe M, Le Grice SFJ. Characterizing and circumventing sequence restrictions for synthesis of circular RNA in vitro. Nucleic Acids Res. 2021;49:e35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034654</ArticleId><ArticleId IdType="pubmed">33406226</ArticleId></ArticleIdList></Reference><Reference><Citation>Puttaraju M, Been MD. Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons. Nucleic Acids Res. 1992;20:5357â64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC334342</ArticleId><ArticleId IdType="pubmed">1279519</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018;9:2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035260</ArticleId><ArticleId IdType="pubmed">29980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CX, Guo SK, Nan F, Xu YF, Yang L, Chen LL. RNA circles with minimized immunogenicity as potent PKR inhibitors. Mol Cell. 2022;82:420â34.</Citation><ArticleIdList><ArticleId IdType="pubmed">34951963</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Z, Zhao Y, Hou Q, Zhu J, Zhai M, Li D, Clean-PIE: a novel strategy for efficiently constructing precise circRNA with thoroughly minimized immunogenicity to direct potent and durable protein expression. bioRxiv. 2022. 2022. 06. 20.496777.</Citation></Reference><Reference><Citation>Chen R, Wang SK, Belk JA, Amaya L, Li Z, Cardenas A. et al. Engineering circular RNA for enhanced protein production. Nat Biotechnol. 2023;41:262â72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931579</ArticleId><ArticleId IdType="pubmed">35851375</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahley MR, Strobel SA. Structural evidence for a two-metal-ion mechanism of group I intron splicing. Science. 2005;309:1587â90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16141079</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YG, Chen R, Ahmad S, Verma R, Kasturi SP, Amaya L. et al. N6-Methyladenosine Modification Controls Circular RNA Immunity. Mol Cell. 2019;76:96â109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778039</ArticleId><ArticleId IdType="pubmed">31474572</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YG, Kim MV, Chen X, Batista PJ, Aoyama S, Wilusz JE. et al. Sensing Self and Foreign Circular RNAs by Intron Identity. Mol Cell. 2017;67:228â38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610545</ArticleId><ArticleId IdType="pubmed">28625551</ArticleId></ArticleIdList></Reference><Reference><Citation>Piao X, Yadav V, Wang E, Chang W, Tau L, Lindenmuth BE. et al. Double-stranded RNA reduction by chaotropic agents during in vitro transcription of messenger RNA. Mol Ther Nucleic Acids. 2022;29:618â24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9421179</ArticleId><ArticleId IdType="pubmed">36090758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39:e142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241667</ArticleId><ArticleId IdType="pubmed">21890902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976;73:3852â6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431239</ArticleId><ArticleId IdType="pubmed">1069269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475â90.</Citation><ArticleIdList><ArticleId IdType="pubmed">32366901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Wang W, Zhou Q, Chen C, Yuan W, Liu J. et al. Roles of circRNAs in the tumour microenvironment. Mol Cancer. 2020;19:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6977266</ArticleId><ArticleId IdType="pubmed">31973726</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Zhang K, Tan S, Xin J, Yuan Q, Xu H. et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. Mol Cancer. 2021;20:13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798340</ArticleId><ArticleId IdType="pubmed">33430880</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CK, Cheng R, Demeter J, Chen J, Weingarten-Gabbay S, Jiang L. et al. Structured elements drive extensive circular RNA translation. Mol Cell. 2021;81:4300â18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8567535</ArticleId><ArticleId IdType="pubmed">34437836</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen SY, Qadir J, Yang BB. Circular RNA translation: novel protein isoforms and clinical significance. Trends Mol Med. 2022;28:405â20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35379558</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Wang Z. IRES-mediated cap-independent translation, a path leading to hidden proteome. J Mol Cell Biol. 2019;11:911â9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884710</ArticleId><ArticleId IdType="pubmed">31504667</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y. et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27:626â41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520850</ArticleId><ArticleId IdType="pubmed">28281539</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe BT, Wesselhoeft RA, Chen R, Anderson DG, Chang HY. Circular RNA migration in agarose gel electrophoresis. Mol Cell. 2022;82:1768â77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9081248</ArticleId><ArticleId IdType="pubmed">35358469</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Zhao F, He M, Fang Y, Ma X, Lu S. et al. An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants. J Control Release. 2024;366:479â93.</Citation><ArticleIdList><ArticleId IdType="pubmed">38184234</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T, Balsera-Manzanero M, Rojo-Fernandez A, Escalera A, Salamanca-Rivera C, Pachon J. et al. Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines. Emerg Microbes Infect. 2024;13:2292068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10798284</ArticleId><ArticleId IdType="pubmed">38054302</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L, Yi Z, Shen Y, Lin L, Chen F, Xu Y. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell. 2022;185:1728â44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8971115</ArticleId><ArticleId IdType="pubmed">35460644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi Z, Qu L, Tang H, Liu Z, Liu Y, Tian F. et al. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat Biotechnol. 2022;40:946â55.</Citation><ArticleIdList><ArticleId IdType="pubmed">35145313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zhu J, Sun J, Chen Y, Du Y, Tan Y. et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol Ther Nucleic Acids. 2022;30:184â97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9482165</ArticleId><ArticleId IdType="pubmed">36156907</ArticleId></ArticleIdList></Reference><Reference><Citation>Katrekar D, Yen J, Xiang Y, Saha A, Meluzzi D, Savva Y. et al. Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs. Nat Biotechnol. 2022;40:938â45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9232839</ArticleId><ArticleId IdType="pubmed">35145312</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang R, He Z, Zhao KT, Zhu H, Hu J, Liu G, Prime editing using CRISPR-Cas12a and circular RNAs in human cells. Nat Biotechnol. 2024.</Citation></Reference><Reference><Citation>Garber K. Orna Therapeutics: circular logic. Nat Biotechnol. 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>